CORE
CO
nnecting
RE
positories
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Research partnership
About
About
About us
Our mission
Team
Blog
FAQs
Contact us
Community governance
Governance
Advisory Board
Board of supporters
Research network
Innovations
Our research
Labs
research
Administration of hepatic stimulatory substance alone or with other liver growth factors does not ameliorate acetaminophen‐induced liver failure
Authors
Abecassis
Bontempo
+39 more
Bravo
Clavien
Farivar
Fausto
Francavilla
Francavilla
Francavilla
Francavilla
Francavilla
Francavilla
Fujiwara
Fujiwara
Gohda
Gove
Harrison
Kawakita
Kirsch
Lewis
Lewis
Lewis
Lindroos
McKeown
Michalopoulos
Milandri
Minuk
Miyachi
Miyazaki
Nakamura
Okuda
Panella
Saunders
Starzl
Starzl
Starzl
Starzl
Takahashi
Tsubouchi
Van Assendelfp
Zarnegar
Publication date
1 January 1993
Publisher
'Wiley'
Doi
View
on
PubMed
Abstract
Sixty‐two beagle dogs were given three doses of acetaminophen over a period of 24 hr in a fulminant liver failure model that is 70% lethal in 72 hr. Treatment of the animals with hepatic stimulatory substance alone or in a mixture with insulin, transforming growth factor‐α and insulin‐like growth factor II had no effect on mortality. Evidence of maximum regeneration with a mitotic index 20 to 25 times resting was the same in treated and untreated animals. Similarly, the biochemical and hematological indexes of liver injury were unaffected by therapy. These studies illustrate the futility of treating fulminant liver failure with exogenous growth factors that apparently are already present in large amounts in the natural response to liver injury. The results suggest that on‐going liver injury by mechanisms other than lack of growth factors is the central problem of fulminant liver failure. If so, provision of regeneration‐stimulating substance is an inappropriate therapeutic strategy. (HEPATOLOGY 1993;17:429–433.) Copyright © 1993 American Association for the Study of Liver Disease
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 16/02/2019
Archivio Istituzionale della Ricerca- Università degli Studi di Foggia
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:fair.unifg.it:11369/120080
Last time updated on 03/09/2019
Archivio istituzionale della ricerca - Università di Padova
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:www.research.unipd.it:1157...
Last time updated on 12/11/2016
D-Scholarship@Pitt
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:d-scholarship.pitt.edu:483...
Last time updated on 19/07/2013